Analyst Price Target is $15.00
▲ +191.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Neuronetics in the last 3 months. The average price target is $15.00, with a high forecast of $21.00 and a low forecast of $12.00. The average price target represents a 191.83% upside from the last price of $5.14.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Neuronetics. This Buy consensus rating has held steady for over two years.
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.